Bloomberg -- Pfizer Inc. (PFE) investors are pushing for a spinoff of the drugmaker’s nutrition business that would command a price tag of $6.8 billion and deliver more than twice the gains of the U.S. stock market.
Bloomberg -- Pfizer Inc. (PFE) investors are pushing for a spinoff of the drugmaker’s nutrition business that would command a price tag of $6.8 billion and deliver more than twice the gains of the U.S. stock market.
